Marc Mazur

Operates as an autologous cell and gene therapy company focused on development of personalized biologics to treat rare skin and connective tissue diseases

Provides investment banking, asset, wealth management and platform services

Provides investment advice and security brokerage services

Provides behavior therapy, alternative and education programs solutions for children & young adults

Functions as a College/University

Operates as a biotechnology company that develops and commercializes regenerative tissue products & biomaterials

Designs, manufactures and markets respiratory medical products

Brevan Howard uses a macro and relative value investment approach focusing primarily on fixed-income and foreign exchange

THVC's deal flow leverages the firm's direct access to investment opportunities developed through research within Tsinghua University, and to the university's network of alumni. The firm targets academic or business projects which they think have potential to develop into stand-alone companies. They favor sectors including information technology, life sciences and products and other advanced technology fields. They seek to invest in projects with a well-developed business plan, committed management with proven leadership abilities, near profitability with significant revenues or the potential for high revenue growth, and a credible strategy to achieve and sustain market leadership. They support their portfolio companies by providing them with access to their established network, financial and management advisory and investment bank services. THVC may invest foreign currency in their portfolio companies through offshore vehicles, to facilitate IPOs on overseas exchanges.